A Pilot Study to Assess the Efficacy and Safety of a Novel Device (VIZO Glasses) in the Management of ADHD in Adults
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- ADHD
- Sponsor
- VIZO Specs Ltd
- Enrollment
- 108
- Locations
- 1
- Primary Endpoint
- Adult ADHD Self-Report Scale (ASRS) - Total Score at Baseline and 2 Months Follow up
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This is a 2-months study, where eligible ADHD adult participants will be provided with personalized VIZO glasses.
Detailed Description
This study was designed as a pilot single-center, open-label study of 2 months treatment. Following the enrollment, the participants will go through an adjustment process where they will be fitted with a personalized pair of VIZO Glasses. The participants will be instructed to wear the glasses throughout the day for two months. A follow-up visit at the end of the 2-month treatment will be conducted to assess the efficacy of VIZO Glasses on managing ADHD symptoms, using the Conners Continuous Performance Test-3, the Adult ADHD Self-Report Scale (ASRS), Behavior Rating Inventory of Executive Function Adults (BRIEF-A), and Clinical Global Impression-Improvement (CGI-I) .
Investigators
Eligibility Criteria
Inclusion Criteria
- •Documented history of primary ADHD diagnosis by certified clinicians
- •Age 18-40 y
- •Written informed consent
- •Able and willing to complete all required ratings and assessments
- •Exclusion criteria:
- •Any current psychiatric / neurological comorbidity (e.g., epilepsy, Autism, depression, TBI, etc), other than ADHD
- •ADHD Medications (stimulants, non-stimulants, other)
- •Neurofeedback, cognitive training
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Adult ADHD Self-Report Scale (ASRS) - Total Score at Baseline and 2 Months Follow up
Time Frame: Baseline, 2 months
The Adult ADHD Self-Report Scale (ASRS) is a self-report instrument that comprises eighteen items that correspond with the DSM-V-TR criteria for ADHD. Subjects are asked to rate 18 symptom items using a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Total scores range from 0 to 72, based on the sum of all 18 questions. Higher scores mean more symptoms and higher ADHD's impairments. Lower values represent better outcomes. The ASRS has two subscales that can be used to identify ADHD subtypes - Inattentiveness and Hyperactivity/Impulsivity. Each subscale contains 9 questions.
Adult ADHD Self-Report Scale (ASRS) - Inattentiveness Subscale Score at Baseline and 2 Months Follow up
Time Frame: Baseline, 2 months
The inattentiveness sub-scale of the ASRS measures difficulties with focusing on details, organisation, remembering appointments, making careless mistakes, and concentration. It includes 9 symptom items using a 5-point Likert scale ranging from 0 ('Never') to 4 ('Very Often'). Total scores range from 0 to 36, based on the sum of all questions. Higher scores mean more symptoms and higher inattentiveness' impairments.
Secondary Outcomes
- Clinical Global Impression-Improvement (CGI-I) - Rate at 2 Months Follow up(2 months)
- Conners' Continuous Performance Test-3 (CPT-3) - Detectability (d') at Baseline and 2 Months Follow up(Baseline, 2 months)
- Behavior Rating Inventory of Executive Function Adult Version (BRIEF-A) - Metacognitive Index - at Baseline and 2 Months Follow up(Baseline, 2 months)